Print Preview Area

SIL index including stage, soluble interleukin-2 receptor, and LDH is as a useful prognostic predictor in DLBCL
Cancer Science, 05/21/2012

Tomita N et al. – The soluble interleukin index is a simple and objective prognostic index for diffuse large B–cell lymphoma (DLBCL) patients to identify candidates for experimental therapy other than Rituximab (R) plus CHOP chemotherapy (R–CHOP).

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Physician Assistant Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

SIL index including stage, soluble interleukin-2 receptor, and LDH is as a useful prognostic predictor in DLBCL Cancer Science, 05/21/2012

SIL index including stage, soluble interleukin-2 receptor, and LDH is as a useful prognostic predictor in DLBCL
Cancer Science, 05/21/2012